Kiadis Pharma N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
20 okt 2015 - 07:00
Statutaire naam
Kiadis Pharma N.V.
Titel
Kiadis Pharma announces enrolment of first patient in its repeat-dosing Phase II clinical trial with ATIR101™
Bericht
Amsterdam, The Netherlands, October 20, 2015 – Kiadis Pharma N.V. (“Kiadis Pharma” or “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative T-cell immunotherapy treatments for blood cancers and inherited blood disorders, today announces that the first patient has been enrolled into its repeat-dosing Phase II clinical trial, CR-AIR-008, with its lead product ATIR101™. The patient was enrolled in Hamilton, Canada within a month of receiving regulatory approval for the study from the Canadian authorities.
Datum laatste update: 25 december 2025